| Toggle Summary
|
Sinexus Welcomes New CEO and Completes Series B
|
|
| Toggle Summary
|
Sinexus changes name to Intersect ENT, Initiates Pivotal Study
|
|
| Toggle Summary
|
Intersect ENT Closes Series C Financing, Recognized for Clinical Science
|
|
| Toggle Summary
|
Intersect ENT Announces U.S. Food and Drug Administration Approval for First Drug Releasing Implant for Chronic Sinusitis Patients
|
|
| Toggle Summary
|
Intersect ENT Announces Positive Data from Pivotal Study of Propel Implant, Showing Significantly Improved Outcomes For Sinus Surgery
|
|
| Toggle Summary
|
Intersect ENT Quadruples Operation Size with Expansion to New Facility in Menlo Park, Calif.
|
|
| Toggle Summary
|
Groundbreaking Clinical Evidence Demonstrates Benefit of PROPEL Implant for Chronic Sinusitis Patients
|
|
| Toggle Summary
|
Intersect ENT Announces FDA Approval of New Steroid-Releasing Implant, Allowing More Chronic Sinusitis Patients to Benefit from Localized Drug Delivery
|
|
| Toggle Summary
|
Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients
|
|
| Toggle Summary
|
Intersect ENT Raises $30 Million Funds to Fuel Commercial Expansion and Development of Next Generation Products for Chronic Sinusitis Sufferers
|
|
